University College Utrecht

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer

Retrieved on: 
Thursday, November 16, 2023

Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).

Key Points: 
  • Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
  • View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
    Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
    Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies.
  • Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
  • Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.

Abalos Therapeutics Appoints Thomas Bogenrieder as Chief Medical Officer

Retrieved on: 
Tuesday, October 18, 2022

Abalos Therapeutics announced today the appointment of Thomas Bogenrieder, MD, PhD, as Chief Medical Officer.

Key Points: 
  • Abalos Therapeutics announced today the appointment of Thomas Bogenrieder, MD, PhD, as Chief Medical Officer.
  • I value the opportunity to join a great team focused on meeting the needs of cancer patients with a scientifically distinct approach that has the potential to change the treatment paradigm in solid tumors, commented Thomas Bogenrieder, Chief Medical Officer of Abalos.
  • Prior to his role at Abalos, Dr. Bogenrieder served as Chief Clinical Officer for AMAL Therapeutics, where he oversaw the clinical development of cancer vaccine candidates in combination with an oncolytic virus.
  • Before AMAL, he served as Chief Medical Officer at Evaxion Biotech, a public company creating AI-driven, neoepitope-targeting personalized cancer immunotherapies and vaccines against infectious diseases.

Last Chance to Register for This Biosimilars Training Course: Covering the Regulatory Pathways and Challenges for Both the EU and US (October 11-12, 2022) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022

in Pharmaceutical Medicine from the University of Surrey (UK) and has worked in the pharmaceutical industry for more than 35 years, primarily at global or European headquarters sites.

Key Points: 
  • in Pharmaceutical Medicine from the University of Surrey (UK) and has worked in the pharmaceutical industry for more than 35 years, primarily at global or European headquarters sites.
  • He has gained a wealth of experience and a comprehensive view on what information is needed to evaluate the benefit/risk ratio of drugs for patients and healthy volunteers.
  • He applies new technologies and Artificial Intelligence to facilitate the business and let people focus on what they can do best.
  • Also, she contributed to the ongoing IMI PREFER project in Europe, focused on the generation and use of patient preference data.

Intravacc publishes 2021 annual report and announces expansion of its management team and board of directors

Retrieved on: 
Tuesday, July 5, 2022

In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.

Key Points: 
  • In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.
  • The annual report for the financial year 2021, including a review of figure, performance and Financial Statements for the Year ended 31 December 2021, is available online here and can also be downloaded as PDF.
  • A summary of Intravacc's financials are also published in the Annual Report Management of State Participations 2021 ( page 165-168, in Dutch ).
  • Furthermore, Intravacc B.V. is very pleased with the expansion of its management team and board of directors.

Intravacc publishes 2021 annual report and announces expansion of its management team and board of directors

Retrieved on: 
Tuesday, July 5, 2022

In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.

Key Points: 
  • In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.
  • The annual report for the financial year 2021, including a review of figure, performance and Financial Statements for the Year ended 31 December 2021, is available online here and can also be downloaded as PDF.
  • A summary of Intravacc's financials are also published in the Annual Report Management of State Participations 2021 ( page 165-168, in Dutch ).
  • Furthermore, Intravacc B.V. is very pleased with the expansion of its management team and board of directors.

Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

Retrieved on: 
Tuesday, February 22, 2022

Sanofis Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

Key Points: 
  • Sanofis Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
    Paris, February 22, 2022.
  • Melanie Lee and Carole Piwnica will leave the Board of Directors.
  • Carole Ferrand is currently Chief Financial Officer of the Capgemini Group and Director of Fnac Darty.
  • Then, she served on the Board of Directors of Capgemini for two years (2016-2018) before being appointed to her current position as Group CFO.